Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease - Wikidata - awgldk - TriplyDB

Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease

Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease

http://www.wikidata.org/entity/Q29346490

about

Neuroimaging of Parkinson's disease: Expanding views.Adenosine receptors as drug targets--what are the challenges?Neuroimaging in Parkinson disease: from research setting to clinical practice.Effects of adenosine receptor antagonists in MPTP mouse model of Parkinson's disease: mitochondrial DNA integrity.Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review.Striatal adenosine A2A receptor expression is controlled by S-adenosyl-L-methionine-mediated methylation.Uncovering caffeine's adenosine A2A receptor inverse agonism in experimental parkinsonism Untangling dopamine-adenosine receptor-receptor assembly in experimental parkinsonism in rats Automated reference region extraction and population-based input function for brain [(11)C]TMSX PET image analyses.Anti-inflammatory or proinflammatory effect of an adenosine receptor agonist on the Th17 autoimmune response is inflammatory environment-dependent Imaging insights into basal ganglia function, Parkinson's disease, and dystonia An A2B Adenosine Receptor Agonist Promotes Th17 Autoimmune Responses in Experimental Autoimmune Uveitis (EAU) via Dendritic Cell Activation.A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease A2B adenosine receptor activation switches differentiation of bone marrow cells to a CD11c(+)Gr-1(+) dendritic cell subset that promotes the Th17 response.Caffeine consumption and risk of dyskinesia in CALM-PD.Adenosine A2A receptors in secondary progressive multiple sclerosis: a [(11)C]TMSX brain PET study.Guanosine and its role in neuropathologies.Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?Maladaptive Synaptic Plasticity in L-DOPA-Induced Dyskinesia Adenosine A2A Receptor Gene Knockout Prevents l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia by Downregulation of Striatal GAD67 in 6-OHDA-Lesioned Parkinson's Mice.Adenosine receptor targeting in health and disease.Adenosine A2A antagonists in Parkinson's disease: what's next?New synaptic and molecular targets for neuroprotection in Parkinson's disease.Dyskinesias in Parkinson's disease: views from positron emission tomography studies.Development of (18)F-labeled radiotracers for neuroreceptor imaging with positron emission tomography Molecular imaging of levodopa-induced dyskinesias.The role of T regulatory cells in immunopathogenesis of myasthenia gravis: implications for therapeutics.Rational drug discovery design approaches for treating Parkinson's disease.mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.New and emerging medical therapies in Parkinson's disease.Immune Alterations in CD8(+) T Cells Are Associated with Neuronal C-C and C-X-C Chemokine Receptor Regulation Through Adenosine A2A Receptor Signaling in a BTBR T(+) Itpr3(tf)/J Autistic Mouse Model.Potential Therapeutic Applications of Adenosine A2A Receptor Ligands and Opportunities for A2A Receptor Imaging.Dopamine-Induced Changes in Gαolf Protein Levels in Striatonigral and Striatopallidal Medium Spiny Neurons Underlie the Genesis of l-DOPA-Induced Dyskinesia in Parkinsonian Mice PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.Synthesis and Characterization of a New Bivalent Ligand Combining Caffeine and Docosahexaenoic Acid.Striatal adenosine A2A receptor neurons control active-period sleep via parvalbumin neurons in external globus pallidus.Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.The effect of istradefylline for Parkinson's disease: A meta-analysis.Behavioral control by striatal adenosine A2A -dopamine D2 receptor heteromers.Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.

P2860

Q28387732-46108212-5DF5-4865-AA8F-01AD63BCE39A Q29346491-6BFBE00D-838E-4B10-A881-AFBA793D6105 Q30868628-A9A4C281-1F37-429E-8E1C-1EA710C1E906 Q33645993-F27F1C3E-8AD5-4BC1-BA48-6CD65A307FAF Q33971113-90D06085-51B7-4448-9890-6BF019B0788C Q34123200-6DF1B85F-3BDA-4C6E-ADB5-959CA644CB02 Q34576218-2635A92A-02E9-43E1-87E1-D6BE31BFF7A8 Q34818322-226443E0-02FA-4072-9CDC-BB81B7CB47D7 Q34957647-64DB5E6F-292C-428B-875E-A4020462A760 Q34988261-16C98E89-B808-49E2-9D15-7F71EF8BC6DD Q35193033-7948E7ED-A3CE-4773-BE26-3A5F044284BF Q35683809-FBF7739B-3EBC-4140-8BC6-1189950A0494 Q36057652-0334A804-1CB3-426C-BBA3-FA05FFFD6602 Q36410586-798EC478-0DC7-42DE-854B-8E97432E2867 Q36717838-0C9210C3-A6FC-44A6-8DC6-3081573F0034 Q37150330-66FE6021-0CC0-4B72-8C98-349C245A4D23 Q37256409-9DBEACA7-6F11-44EB-83B9-A7BFEA5E97BE Q37506507-6227C348-4A50-4460-8D1B-5738FFC02B05 Q37516434-EF202364-91A3-4D99-94C7-406B78ECBEAD Q37712460-F39E96D5-99AB-4035-9929-23062F50672D Q37948081-530ED8D0-14EF-4485-A29C-CC5953B03F0F Q38010070-7257C487-483B-4A97-9714-7595D82421E0 Q38038559-5EF210A5-E999-48F1-88C0-A31BEEFBF074 Q38182651-6B847491-B851-4EF9-A782-AC6F01C7E3B2 Q38244707-D4974ADF-B66A-473A-8EFA-CC146AE2E46D Q38355582-3F7B08B2-77D1-44A6-B410-5F80EADD5FAC Q38479391-EE18D2C1-A701-43C2-B2DF-F5D6E4F1ABCA Q38520864-37D58160-DF5E-4DA3-AB56-BCA9C465B0A5 Q38660240-04F1ADDF-BF3F-45CA-A071-3BA956C96F06 Q38718194-9EE4B5D0-348B-4C55-BEDF-A7AAA1090131 Q38728524-740BAC16-8177-4704-B6FC-50625EF3937F Q38765118-525CBECA-050C-46D7-9860-20A4BD0436EB Q42322627-DCF5CD76-103D-426E-A81D-2F178A38CD82 Q42369736-EC920CD2-9C12-44D2-80D0-DB9A02D0063F Q42506560-52717667-C432-48D6-9EA4-AF5283804DE9 Q42637831-E8D45830-DF4D-4930-9FEA-B7EAC5DB96FA Q46354756-96ADE134-AB94-4A0C-A576-607216D59DF1 Q47138950-DB5C2004-DEC7-43BF-A461-07E0CA0EE17A Q47624646-74CA410A-304F-4767-A93C-E7837FD9218D Q47648607-78DF1314-6FAF-42D0-9646-1060449D93B3

P2860

Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease

http://www.wikidata.org/entity/Q29346490

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Adenosine 2A receptor availabi ...... atients with Parkinson disease

@ast

Adenosine 2A receptor availabi ...... atients with Parkinson disease

@en

type

label

Adenosine 2A receptor availabi ...... atients with Parkinson disease

@ast

Adenosine 2A receptor availabi ...... atients with Parkinson disease

@en

prefLabel

Adenosine 2A receptor availabi ...... atients with Parkinson disease

@ast

Adenosine 2A receptor availabi ...... atients with Parkinson disease

@en

P1433

Q29346490-B22B400F-7196-404C-A183-D8A9E88186EC

P1476

Q29346490-3DA2324F-FB81-4963-A51D-D2353A66626A

P2093

Q29346490-140A60F8-2567-4287-8C5B-7B5BA4538D18

Q29346490-62CC519B-C428-44ED-8674-9B543A0BC87E

Q29346490-8FAAF0D1-1151-48C5-B750-E38D4BD3510C

P2860

Q29346490-01C67E36-666F-43A2-8DF8-35263A31AF6C

Q29346490-05916544-EC2B-4AAA-A7D2-0185EEC750B5

Q29346490-086C4F50-78CF-4C36-9684-18C211F5D464

Q29346490-09BE3B16-FB9D-4365-AD73-AE2B27CAADC1

Q29346490-115A4F52-CFB3-4A43-A06D-110EC70EC860

Q29346490-126B4D82-D688-44C3-887E-8E8A2C7AAB7B

Q29346490-1B8EF7AA-496E-437D-8B31-1F8A97D78B1E

Q29346490-220EBD08-3700-4DD3-9030-BF6B66CD749A

Q29346490-37B19AA0-F523-4B8E-8F4C-3B6A00AEF006

Q29346490-3B3BA9D1-4EC5-4448-AAEF-362E76685B31

P304

Q29346490-1CB7019F-3BB4-40FC-AD58-E5C7C2BF3FA8

P31

Q29346490-758DD6A1-B410-448C-934F-0FB05DF259C0

P356

Q29346490-B47FDAC9-FC46-407C-8DA4-164E34F8A8E2

P407

Q29346490-F812820C-5B85-438E-B82E-4EDCD3EA61E9

P433

Q29346490-32D92B53-CDDE-4917-A1C2-D727A5D6F682

P478

Q29346490-2055F8A4-4ED9-4B67-860B-109F7EFB3E9B

P50

Q29346490-8A0CED64-AA87-4DDD-AE75-FAA975E7F205

Q29346490-9BEB3A2C-4677-413D-9492-28F2641D16FA

Q29346490-EAC50896-AFAE-46F6-916A-E555DBACE81E

P577

Q29346490-56BA3FA8-691A-44C2-A764-9DB3C83FDF4F

P698

Q29346490-3ADD12B7-1AFB-4813-8223-CDDD4F974F07

P921

Q29346490-3D5786C9-1A88-40BF-9FC4-B0A61CD9774B

Q29346490-B710C6BC-9DA0-40F8-BBFE-018F08C83D69

P932

Q29346490-8A021447-F43F-4D91-B183-A9FC2AE878BD

P356

WNL.0B013E31821CCCE4

P1433

P1476

Adenosine 2A receptor availabi ...... atients with Parkinson disease

@en

P2093

A F Ramlackhansingh

http://www.w3.org/2001/XMLSchema#string

I Ahmed

http://www.w3.org/2001/XMLSchema#string

S K Bose

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of the Potent and Highly Selective A(2A) Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyraz olo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of

Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA

Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.

Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A(2A) receptor system using positron emission tomography.

Distribution, biochemistry and function of striatal adenosine A2A receptors.

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.

In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416.

Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).

Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease.

P304

1811-1816

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0B013E31821CCCE4

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P50

David J. Brooks

Federico Turkheimer

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21606452

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3100120

http://www.w3.org/2001/XMLSchema#string